Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood test could spot colon cancer before it spreads

NCT ID NCT06342440

Diagnosis Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study is testing a new blood test called DENEB that looks for tiny molecules (microRNAs) to find colorectal cancer and precancerous polyps early. Researchers will collect blood samples from 2,000 people who are also getting a colonoscopy. The goal is to see if the blood test is accurate and could one day offer a simpler, less invasive way to screen for colorectal cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
DENEB blood test (measures microRNA levels)
What this could lead to
If successful, this blood test could offer a simple, non-invasive way to catch colorectal cancer and precancerous polyps early, potentially saving lives through earlier treatment.
What could go wrong
This is an early-stage study still recruiting participants. The test may not be accurate enough to replace colonoscopy, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2020

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Three independent cohorts of individuals who belong to one of the following four * Negative colonoscopy findings * Low-risk adenomas (at most) * Advanced adenomas (at most) * Colorectal cancer

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All individuals included in the study need to have had a colonoscopy at the time of blood sampling. * Received standard diagnostic and staging (as necessary) procedures as per local guidelines, and at least one sample was drawn before receiving any curative-intent treatment. * Received standard pathological and endoscopic diagnosis and assessment for cohort assignment. Exclusion Criteria: * Hereditary colorectal cancer syndromes (identified through genetic testing). * Inflammatory bowel diseases. * Lack of written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

adenomatous colon polyp colon dysplasia colonic neoplasm colorectal adenocarcinoma colorectal adenoma colorectal cancer colorectal carcinoma colorectal neoplasm colorectal serrated adenocarcinoma hereditary mixed polyposis syndrome polyp of large intestine polyposis syndrome, hereditary mixed, 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal adenocarcinoma Colorectal adenocarcinoma metastatic in the liver Colorectal adenoma and carcinoma 1 Colorectal adenoma with mild dysplasia Colorectal adenoma with moderate dysplasia Colorectal adenoma with severe dysplasia Colorectal adenomatous polyp Colorectal cancer Colorectal cancer stage I Colorectal cancer stage II Colorectal cancer stage III Colorectal cancer stage IV Colorectal disorders Colorectal dysplasia Colorectal neoplasms Colorectal neoplasms malignant Colorectal polyp Colorectal serrated adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barcelona University

    RECRUITING

    Barcelona, Spain

  • City of Hope Medical Center

    RECRUITING

    Monrovia, California, 91016, United States

  • IRCCS San Raffaele

    RECRUITING

    Milan, Italy

  • Mie University

    RECRUITING

    Mie, Japan

  • The First Affiliated Hospital of Dalian Medical University

    RECRUITING

    Dalian, China

  • University of California San Diego

    RECRUITING

    San Diego, California, 92093, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.